Yahoo Web Search

Search results

  1. 6 days ago · Shockwave offers the first and only commercially available intravascular lithotripsy (IVL) platform for coronary artery disease (CAD) and peripheral artery disease (PAD) and complements Johnson & Johnson’s leading positions in heart recovery (Abiomed) and electrophysiology (Biosense Webster) to make it a category leader in four of the largest ...

  2. 6 days ago · Strengthens Position in Highest-Growth, Innovation-Oriented Segments of Cardiovascular Intervention Creates Greater Opportunity to Transform the Treatment Landscape for Cardiovascular Disease Johnson Johnson (NYSE: JNJ) today announced it has completed its acquisition of Shockwave Medical. Shockwave is now part of Johnson Johnson and will operate as a business unit within Johnson Johnson ...

  3. 3 days ago · In this article: Johnson & Johnson (J&J) has closed the acquisition of SS-based cardiovascular device developer Shockwave Medical. The deal between the parties was signed in April. As part of the ...

  4. 6 days ago · On April 5, the companies announced a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Shockwave for $335.00 per share in cash, corresponding to an enterprise value of approximately $13.1 billion including cash acquired. The transaction was approved by both companies’ boards of directors.

  5. 6 days ago · Shockwave offers the first and only commercially available intravascular lithotripsy (IVL) platform for coronary artery disease (CAD) and peripheral artery disease (PAD) and complements Johnson &...

  6. 6 days ago · Shockwave Medical adds capabilities to treat calcified plaques Shockwave’s IVL technology was designed to target severely calcified plaques in the coronary and peripheral arteries with shockwaves, clearing the way for cardiologists before percutaneous coronary intervention operations.

  7. 6 days ago · Johnson & Johnson has completed its acquisition of Shockwave Medical. Shockwave will now operate as a Johnson & Johnson MedTech business unit. The $13.1 billion deal was first revealed in April 2024. The transaction broadens the company’s market share in cardiovascular intervention.

  8. People also ask

  1. People also search for